Final Public Disclosure and Verification of the Five-Year New Drug Review System

The U.S. Food and Drug Administration (FDA) is scheduled to hold a public meeting on September 16, 2026, to discuss the PDUFA VIII reauthorization recommendation. The application period is for the fiscal years 2028-2032, and the current PDUFA VII will end on September 30, 2027. This meeting is a process to verify the results of the public opinion collection that began on July 14, 2025, and the negotiations between the FDA, the Pharmaceutical Research and Manufacturers of America (PhRMA), and the Biotechnology Innovation Organization (BIO). It is important to note that this is not the first negotiation session but rather a stage of adjusting the recommendation before submission to Congress. The final version is scheduled to be submitted to Congress by January 15, 2027.

Predictability of Review is More Important Than Fees

PDUFA is a system that supports the review of new drug applications (NDAs) and biologics license applications (BLAs) with industry fees and imposes performance goals on the FDA. The FY2026 application fee, including clinical data, is $4,682,003, which is 8.6% higher than the $4,312,000 in FY2025. Applications that do not require clinical data are $2,341,002, and the annual program fee for approved products is $442,213. However, there are exemption and reduction pathways for orphan drug-designated indications and small businesses with limited resources, so not all early-stage biotech companies bear the same cost. From an investment perspective, the predictability of the first review cycle and improved communication between the FDA and sponsors have a greater impact on the cash burn period and launch timing than the absolute amount of fees.

Actual Agenda of the PDUFA VIII Negotiation

The disclosed negotiation records include real-world evidence (RWE), rare disease evaluation metrics, model-based drug development (MIDD), label discussions during review, regulatory science, manufacturing and quality (CMC), the lifecycle of facilities, and post-market safety. The FDA and the industry also discussed a third-party analysis to evaluate the reasons for the occurrence of complete response letters (CRLs) and the effectiveness of improved formal meetings. Discussions on maintaining the Sentinel-based, non-interventional post-market research and risk evaluation and mitigation strategies (REMS) are measures to ensure that the expansion of expedited reviews does not lead to a weakening of safety management.

Impact on the Entire Pipeline, Not Specific Drugs

This event does not cover the approval, clinical stage, target molecule, or FDA Advisory Committee (AdComm) vote of individual therapies, nor does it involve any transaction terms. The target market is not a specific indication but the entire U.S. prescription drug NDA/BLA market, and the competitive landscape is reflected in the regulatory pathway competition between standard review and priority review, accelerated approval, and orphan drug support programs rather than drug-to-drug comparisons. Companies in Phase 3 and the approval application stage will be directly affected by the predictability of the review schedule after 2028, and early-stage Phase 1/2 companies should reflect the FDA meeting and evaluation metric design rules in their development plans. The modified recommendation and the legislative results of Congress after the public meeting will determine the actual cost, manpower, and performance goals.